[ad_1]
Pharmaceutical company Pfizer said Wednesday that the final analysis of its clinical trial shows its coronavirus vaccine is 95% effective, has no serious side effects, and protects the elderly.
The results of the final efficacy analysis of the vaccine study were released on Wednesday.
READ MORE: Coronavirus Vaccine Introduction In Canada: Who Will Get It First?
The announcement comes a week after Pfizer revealed promising preliminary results from its Phase 3 studies. The company is now preparing to formally ask US regulators to allow emergency use of the vaccine.
In the Phase 3 study involving more than 43,000 volunteers, half received the experimental vaccine and half received a placebo. Participants received two shots 21 days apart.
Pfizer he said Wednesday that there were 170 cases of coronavirus in his study, including 162 in the placebo group and eight in the vaccine group.
Ten people developed severe COVID-19, one of whom received the vaccine, the data showed.
The results state that the vaccine appears to protect 94% of adults over the age of 65, a demographic that is particularly at risk from the virus.
[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
Pfizer also said the vaccine prevented mild and severe forms of the virus, which was well tolerated and that side effects were mostly mild to moderate and resolved quickly.
The only serious adverse event was fatigue, which affected 3.7% of recipients after the second dose. Older people tended to report fewer milder adverse events following vaccination.
Pfizer has not yet released detailed data on its study and the results have not been analyzed by independent experts.
Pfizer and BioNTech said they plan to produce up to 50 million doses of the vaccine globally in 2020 and up to 1.3 billion doses in 2021.
Read more:
A coronavirus vaccine is almost ready. But do you take it?
Canada signed an agreement with Pfizer in August to secure 20 million doses of the coronavirus vaccine in 2021. Prime Minister Justin Trudeau previously said he hopes to have the vaccine launched in early 2021.
On Tuesday, Moderna announced that its experimental vaccine appears to be 94.5 percent effective after an interim analysis of its late-stage study.
– With files from the Associated Press and Reuters
View link »
© 2020 Global News, a division of Corus Entertainment Inc.
.
[ad_2]
Source link
